Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA7 | P43166 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 5/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | STS | P08842 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7751798 | 0.88 | MAPT (0.49) | CA1CA2CA12CA7CA9 | |
| SCHEMBL4689121 | 0.84 | MEN1 (0.46) | CA1CA2CYP1A2SMN1; SMN2KMT2A | |
| SCHEMBL2574864 | 0.78 | ESR1 (0.44) | CA1CA2CA12CA7CA9 | |
| SCHEMBL87450 | 0.77 | CA1 (0.83) | CA1CA2CA12CA7CA9 | |
| SCHEMBL571045 | 0.76 | CA12 (0.63) | CA1CA2CA12CA7CA9 | |
| SCHEMBL9781670 | 0.76 | LMNA (0.67) | CA1CA2CA12CA7CA9 | |
| SCHEMBL2888233 | 0.76 | CA1 (0.63) | CA1CA2CA12CA7CA9 | |
| SCHEMBL30271267 | 0.75 | CA1 (0.79) | CA1CA2CA12CA7CA9 | |
| SCHEMBL21440358 | 0.75 | CA1 (0.79) | CA1CA2CA12CA7CA9 | |
| SCHEMBL29504635 | 0.75 | CA1 (0.79) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010019828-A1 | GLUCAGON RECEPTOR ANTAGONISTS | METABASIS THERAPEUTICS, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| US-20050113447-A1 | Selective retinoid agonists | BELLONI PAULA N (US) | 2005-05-26 | — | — | US | disclosed |
| US-6828337-B2 | Bicyclic retinods containing ester or acid group; useful for treating emphysema | HOFFMANN-LA ROCHE INC. | 2004-12-07 | — | — | US | disclosed |
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-02 | — | — | US | disclosed |
| EP-1206436-B1 | RETINOIDS FOR THE TREATMENT OF EMPHYSEMA | HOFFMANN LA ROCHE (CH) | 2004-10-13 | — | — | EP | disclosed |
| US-20030176726-A1 | Bicyclic retinods containing ester or acid group; useful for treating emphysema | HOFFMANN-LA ROCHE INC. | 2003-09-18 | — | — | US | disclosed |
| US-6528677-B1 | Such as 4-(4,4,7,7-tetramethyl-2-pentyl-2,3,4,5,6,7-hexa-hydro-1H-indene-2 -ylethynyl)-benzoic acid; emphysema | HOFFMANN-LA ROCHE INC. | 2003-03-04 | — | — | US | disclosed |
| EP-1206436-A2 | RETINOIDS FOR THE TREATMENT OF EMPHYSEMA | F. HOFFMANN-LA ROCHE AG (CH) | 2002-05-22 | — | — | EP | disclosed |
| WO-2001009076-A2 | RETINOIDS FOR THE TREATMENT OF EMPHYSEMA | F. HOFFMANN-LA ROCHE AG (CH) | 2001-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176726-A1 | Bicyclic retinods containing ester or acid group; useful for treating emphysema | RARG, RXRA, RXRG | CA1 4338/4885CA2 3714/4885CA12 3889/4885 |
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | MCHR2, MCHR1, NPY1R | CA1 4351/4885CA2 952/4885CA12 3074/4885 |
| US-20050113447-A1 | Selective retinoid agonists | RARA, RARB, RARG | CA1 4592/4885CA2 4500/4885CA12 3800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.